Abstract:
This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed.
Abstract:
The present invention provides a highly reliable disk apparatus which is reduced in size, thickness and weight, and which can surely prevent the double insertion of disk-shaped recording media with a simple structure to thereby prevent a contact between each of the disk-shaped recording media. In the disk apparatus of the present invention, a disk guide is rotatably held in the proximity of an opening for inserting and ejecting a disk-shaped recording medium, which is formed in the stationary frame fixed to the casing, and the disk guide leads the disk-shaped recording medium to the inserting and ejecting operations and also closes at least a part of the above opening.
Abstract:
In a heat radiating member which has a contact portion to be put into contact with a solid-state image sensor fixed to a prism member, and a fin-like heat radiating portion for radiating heat, which has been transferred through the contact portion, into its surrounding gas, the contact portion and the heat radiating portion are formed from a foil member made of a high heat conductivity material. By mounting the heat radiating member on the solid-state image sensor, there is realized a heat radiating structure for cooling the solid-state image sensor while reducing external-force loads applied to the solid-state image sensor with a relatively simple structure.
Abstract:
A magnetic head is manufactured by grinding a head chip (2) with a gap depth (GD 1) to remove its margin (6) until the gap depth becomes a final gap depth (GD 2). The gap depth (GD 1) is 25 microns or thinner. The method increases yield and productivity in the manufacture of a high performance magnetic head with a decreased gap depth (GD 2), which satisfies the standards of both the gap depth (GD 2) and the distance between the head gap and the outermost point of the chip front.
Abstract:
In processing a head unit in which a head relative height Y is Y′ with a grinding amount &Dgr;GD of &Dgr;GD′, the relationship between distances Bo between a vertex of a curved surface as a front face of a head chip and a head gap before and after grinding the front face of the head chip and a gap depth dimension GD, is predetermined with respect to a head unit in which the head relative height is substantially equal to Y′, through which Bo1 as the value of Bo before grinding corresponding to a target value of the value of Bo after grinding is determined and used as Bo1 of the head unit in which the head relative height Y is Y′. Thus, grinding of the front face of the head chip is conducted after Bo1 corresponding to the target value is determined. Hence, a head unit with the value of Bo after grinding falling within the range of standard values can be manufactured efficiently, and accordingly the yield can be improved.
Abstract:
Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful.
Abstract:
This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.
Abstract:
This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.
Abstract:
This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed.
Abstract:
The present invention is intended to develop a urine pretreatment agent, a urine pretreatment method, and a urinary protein quantitation method which reduce or cancel the influences of urine pH variations, cancel the influences of precipitates of urinary inorganic salts, and solubilize membrane proteins. The present invention provides: a urine pretreatment agent for urinary protein quantitation, comprising a buffer, a chelating agent, and a surfactant; a urine pretreatment method comprising a step of mixing 10 to 1000 parts by mass of the urine pretreatment agent of the present invention with 100 parts by mass of urine; and a urinary protein quantitation method comprising steps of: mixing 10 to 1000 parts by mass of the urine pretreatment agent of the present invention with 100 parts by mass of urine; and then measuring the protein concentration.